The local medical landscape is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in scientific trials for addressing obesity. This https://apollobookmarks.com/story21704037/retatrutide-australia-australia-a-new-prospect-for-weight-loss